Vera Therapeutics has passed its Q2 earnings test and the result was ugly — the stock fell nearly 8% on August 10 following the print, and another 4% the day after, leaving it at $30.29 and down 28% over the past month.
The options market called it right. Heading into the print, the put/call ratio had jumped from a steady 0.35 through July to 0.63 — nearly 1.8 standard deviations above its 20-day average — as traders loaded up on downside protection. That defensive posture proved warranted. With the Q2 release now behind the company, the PCR has barely budged, still running at 0.63 against a 20-day mean of 0.41. Options traders aren't unwinding their hedges. The next print isn't due until November 11, so the sustained put demand reflects ongoing uncertainty about the Trutakna launch trajectory rather than pre-earnings jitters.
Short positioning tells a consistent story. Bears hold 23.8% of the free float short — a position that has grown 28% over the past month, accelerating from roughly 11.9 million shares in early July to 15.2 million now. The sharpest step-up came around July 23, when short interest jumped from 13.6 million to 15.0 million in a single session, and it has held near that elevated level ever since. Despite the size of the short position, the borrow market is anything but stressed: availability is running at 819% — meaning there are roughly eight shares available to borrow for every one currently lent out — well above the 52-week trough of 582%. Cost to borrow remains low at 0.59%, even though it has nearly doubled over the past month from very cheap levels. Heavy short interest with loose borrow conditions is not a squeeze setup.
Analysts moved quickly after the earnings miss. HC Wainwright cut its target from $125 to $90 while keeping its Buy rating; Wedbush trimmed from $43 to $34 on its Neutral. Both moves came within 24 hours of the print. That brings the Street into sharp internal contrast: the consensus mean target is $78.71 — more than 2.5 times the current price — but that average is heavily skewed by Buy-rated houses carrying targets in the $70–$90 range, while the lone Neutral sits at $34, just above where the stock trades. The bull case rests on Trutakna's potential in the large IgAN market, a clean FDA approval for atacicept, and a favorable immunogenicity profile. The bear case is more specific: a crowded market with Otsuka's Voyxact and Asahi Kasei's Filspari already competing, an annual wholesale acquisition cost of $425,000 that may face payer pushback, and early launch execution risk. The ORTEX short score has eased slightly from 65.4 two weeks ago to 63.1 now, but remains elevated, reflecting that this is still a stock where bearish signals dominate the data landscape.
The institutional register provides one counterpoint worth noting. BlackRock added 659,658 shares through July, and State Street added 785,148 — both passive-weight increases, but directionally consistent with the stock's index float. Deep Track Capital disclosed a position of over 4.1 million shares in its Q1 filing, up 3.9 million from the prior quarter. These are not signals of distress selling from long-only holders; the major active names appear to be sitting on their hands rather than exiting.
Founder and CEO Marshall Fordyce has been a consistent seller through the decline — offloading roughly $2 million worth of stock across multiple transactions in June and July, all at prices between $37 and $45, well above current levels. Those sales were executed under a pre-arranged plan, so they carry limited informational weight, but the pattern of selling into strength that no longer exists frames the current price context sharply. The key metric to watch from here is Trutakna's quarterly revenue disclosure in November — that will be the first meaningful read on whether payer coverage is keeping pace with the approved indication and whether the sales force is converting the target patient population at a rate that justifies any of the bullish price targets still on the Street.
See the live data behind this article on ORTEX.
Open VERA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
